Apogee Therapeutics, Inc. is a biotechnology firm, operating via its subsidiary, dedicated to advancing biologic treatments for conditions such as atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and a range of other inflammatory and immunological disorders. Its primary focus includes APG777, a sub…
An institutional-grade, numbers-driven thesis on APGE — generated on demand from live fundamentals, scores and forecast.
Member feature · 7-day free trial · no charge today · cancel anytime
As of August 8, 2026, TradersQuant's model rates Apogee Therapeutics, Inc. (APGE) 54/100 with a 12-month base-case forecast of $125.52 — -6.9% versus the current price of $134.84. Apogee Therapeutics, Inc. trades at $134.84 in the Healthcare sector, with a market capitalisation of $8.34B. The score blends valuation, growth, earnings quality and momentum into a single grade.
The 12-month analyst consensus price target for APGE is $125.52, implying -6.9% versus the current price. The model's 12-month scenario range runs from $186.15 (bear) to $210.34 (bull), with a base case of $195.38.
On the fundamentals, Apogee Therapeutics shows a P/E of -31.1, trailing revenue of $0, revenue growth of +0.0% YoY. This page also tracks APGE's short interest, institutional (smart-money) positioning and the options market — the same cross-signal view institutions watch.
APGE currently carries a TradersQuant composite score of 54/100, which we read as a neutral-to-watch signal. The Wall-Street analyst consensus is "Hold". Our 12-month price target of $125.52 implies -6.9% from $134.84. This is research, not financial advice — always combine it with your own judgement.
The analyst consensus price target for APGE is $125.52, about -6.9% versus the latest price of $134.84. Consensus is based on 14 analysts.
TradersQuant's 12-month model forecast for APGE is a base case of $195.38, ranging from $186.15 (bear) to $210.34 (bull), an expected return of +44.9%. Forecasts are model estimates, not guarantees.
The TradersQuant price prediction for APGE over the next 12 months is $195.38 in the base case (bear $186.15, bull $210.34), versus today's price of $134.84. Unlike black-box prediction sites, every TradersQuant call is logged at the price and date it was made and graded publicly against the S&P 500.
We deliberately don't publish 2030 price predictions for APGE — no model can honestly forecast a single stock five-plus years out, and sites that do are guessing. TradersQuant focuses on a rigorous 12-month bull/base/bear range, refreshed continuously and graded on our public track record.
TradersQuant estimates APGE's fair value at $125.52, implying -6.9% of expected upside versus the current price.
Apogee Therapeutics does not currently pay a dividend.
Data and model outputs are for research only and are not financial advice. Figures update continuously.
